Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Leases: 2021-2025

Historic Current Leases for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Sep 2025 value amounting to $6.4 million.

  • Crinetics Pharmaceuticals' Current Leases fell 13.11% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 13.11%. This contributed to the annual value of $7.2 million for FY2024, which is 71.39% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Current Leases is $6.4 million, which was down 2.56% from $6.6 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Current Leases high stood at $7.4 million for Q2 2024, and its period low was $939,000 during Q4 2021.
  • Its 3-year average for Current Leases is $5.3 million, with a median of $6.4 million in 2025.
  • In the last 5 years, Crinetics Pharmaceuticals' Current Leases surged by 571.33% in 2024 and then dropped by 13.11% in 2025.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Current Leases stood at $939,000 in 2021, then climbed by 11.93% to $1.1 million in 2022, then surged by 297.05% to $4.2 million in 2023, then skyrocketed by 71.39% to $7.2 million in 2024, then dropped by 13.11% to $6.4 million in 2025.
  • Its Current Leases was $6.4 million in Q3 2025, compared to $6.6 million in Q2 2025 and $6.9 million in Q1 2025.